| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Sodium-dependent neutral amino acid transporter B(0)AT1, Solute carrier family 6 member 19, System B(0) neutral amino acid transporter AT1, SLC6A19, B0AT1 |
| Entrez GeneID | 340024 |
| WB Predicted band size | 71.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This SLC6A19 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 544-575 amino acids from human SLC6A19. |
+ +
1. **"SLC6A19 is a novel target for pancreatic β-cell protection/regeneration in diabetes"**
- **作者**: Ahmed et al.
- **摘要**: 研究探讨SLC6A19在糖尿病胰岛β细胞功能中的作用，开发特异性抗体用于Western blot和免疫荧光，证实其通过调节氨基酸转运影响β细胞存活及胰岛素分泌。
2. **"Development and validation of a monoclonal antibody specific for SLC6A19 transporter"**
- **作者**: Zhang et al.
- **摘要**: 描述针对SLC6A19胞外结构域的单克隆抗体制备，通过敲除小鼠模型验证抗体特异性，应用于肾脏和肠道组织中的蛋白定位及表达水平分析。
3. **"SLC6A19 deficiency causes impaired intestinal neutral amino acid transport via disruption of B0AT1-ACE2 complex"**
- **作者**: Camargo et al.
- **摘要**: 利用SLC6A19抗体研究其与ACE2的相互作用，发现其缺失导致氨基酸吸收障碍，抗体用于共免疫沉淀实验证实蛋白复合体的功能依赖性。
4. **"Antibody-based profiling of solute carrier transporters in human tissues"**
- **作者**: Höglund et al.
- **摘要**: 系统性分析SLC家族蛋白在人体组织的分布，包括SLC6A19抗体的免疫组化数据，揭示其在肾脏近端小管的高表达及与代谢疾病的潜在关联。
(注：上述文献信息为示例性质，实际引用请以真实出版物为准。)
The SLC6A19 antibody is a crucial tool for studying the solute carrier family 6 member 19 (SLC6A19), a sodium-dependent neutral amino acid transporter predominantly expressed in the kidney and intestinal epithelial cells. SLC6A19 facilitates the absorption of essential amino acids like leucine, phenylalanine, and tryptophan, playing a vital role in nutrient homeostasis. Research using this antibody has highlighted its involvement in Hartnup disorder, a rare autosomal recessive condition caused by SLC6A19 mutations, leading to impaired amino acid reabsorption and urinary excretion.
The antibody is widely employed in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect SLC6A19 expression levels, tissue localization, and functional interactions. Studies using knockout models and antibody-based assays have linked SLC6A19 dysfunction to metabolic disorders, including type 2 diabetes and obesity, due to its regulatory role in amino acid sensing and mTOR signaling.
Developed in hosts like rabbits or mice, SLC6A19 antibodies target specific epitopes, often within extracellular or cytoplasmic domains, enabling mechanistic insights into transporter regulation, substrate specificity, and pharmacological modulation. These tools are essential for exploring therapeutic strategies targeting amino acid transport in metabolic diseases or nutritional deficiencies.
×
